Rosacea (Dermatology) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rosacea – Drugs In Development, 2021, provides an overview of the Rosacea (Dermatology) pipeline landscape.

Rosacea is a chronic and potentially life-disruptive disorder primarily of the facial skin, often characterized by flare-ups and remissions. Symptoms include frequent redness of the face, or flushing, small, red lines under the skin, a swollen nose and thick skin, usually on the forehead, chin, and cheeks. The predisposing factors include age and family history of rosacea. Treatment includes antibiotics and acne drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rosacea – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Rosacea (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rosacea (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Rosacea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 2, 10, 6, 1 and 9 respectively.

Rosacea (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Rosacea (Dermatology).

– The pipeline guide reviews pipeline therapeutics for Rosacea (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Rosacea (Dermatology) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Rosacea (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Rosacea (Dermatology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Rosacea (Dermatology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Rosacea (Dermatology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Accuitis Pharmaceuticals Inc

AiViva BioPharma Inc

Alfasigma SpA

Amgen Inc

AOBiome LLC

Attillaps Holdings Inc

Biomimetix JV LLC

Botanix Pharmaceuticals Ltd

Cellix Bio Pvt Ltd

Cutanea Life Sciences Inc

Dermata Therapeutics Inc

ELORAC Inc

Emeriti Pharma AB

Evommune Inc

Hovione FarmaCiencia SA

Maruho Co Ltd

Matrisys Bioscience Inc

Perpetuum BV

Promius Pharma LLC

Sol-Gel Technologies Ltd

Sunny Pharmtech Inc

Tarsus Pharmaceuticals Inc

Timber Pharmaceuticals Inc

TWi Biotechnology Inc

Union Therapeutics AS

VYNE Therapeutics Inc

Table of Contents

Table of Contents

Introduction

Rosacea - Overview

Rosacea - Therapeutics Development

Rosacea - Therapeutics Assessment

Rosacea - Companies Involved in Therapeutics Development

Rosacea - Drug Profiles

Rosacea - Dormant Projects

Rosacea - Discontinued Products

Rosacea - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Rosacea, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Companies, 2021 (Contd..1)

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Rosacea – Pipeline by Accuitis Pharmaceuticals Inc, 2021

Rosacea – Pipeline by AiViva BioPharma Inc, 2021

Rosacea – Pipeline by Alfasigma SpA, 2021

Rosacea – Pipeline by Amgen Inc, 2021

Rosacea – Pipeline by AOBiome LLC, 2021

Rosacea – Pipeline by Attillaps Holdings Inc, 2021

Rosacea – Pipeline by Biomimetix JV LLC, 2021

Rosacea – Pipeline by Botanix Pharmaceuticals Ltd, 2021

Rosacea – Pipeline by Cellix Bio Pvt Ltd, 2021

Rosacea – Pipeline by Cutanea Life Sciences Inc, 2021

Rosacea – Pipeline by Dermata Therapeutics Inc, 2021

Rosacea – Pipeline by ELORAC Inc, 2021

Rosacea – Pipeline by Emeriti Pharma AB, 2021

Rosacea – Pipeline by Evommune Inc, 2021

Rosacea – Pipeline by Hovione FarmaCiencia SA, 2021

Rosacea – Pipeline by Maruho Co Ltd, 2021

Rosacea – Pipeline by Matrisys Bioscience Inc, 2021

Rosacea – Pipeline by Perpetuum BV, 2021

Rosacea – Pipeline by Promius Pharma LLC, 2021

Rosacea – Pipeline by Sol-Gel Technologies Ltd, 2021

Rosacea – Pipeline by Sunny Pharmtech Inc, 2021

Rosacea – Pipeline by Tarsus Pharmaceuticals Inc, 2021

Rosacea – Pipeline by Timber Pharmaceuticals Inc, 2021

Rosacea – Pipeline by TWi Biotechnology Inc, 2021

Rosacea – Pipeline by Union Therapeutics AS, 2021

Rosacea – Pipeline by VYNE Therapeutics Inc, 2021

Rosacea – Dormant Projects, 2021

Rosacea – Dormant Projects, 2021 (Contd..1)

Rosacea – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Rosacea, 2021

Number of Products under Development by Companies, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports